Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Relypsa
Marketing
AZ finally wins hard-fought FDA nod for ZS-9, now dubbed Lokelma
Lokelma moved past two rejections to win its nod, and now it's ready to tackle Vifor's hyperkalemia rival Veltassa, approved back in 2015.
Angus Liu
May 21, 2018 11:10am
Galenica snaps up Relypsa for $1.53B in march toward Vifor spinoff
Jul 21, 2016 8:06am
Relypsa's Veltassa launch gets a leg up from AZ's ZS-9 setback
Jun 1, 2016 7:03am
Buyers eye Relypsa and its hyperkalemia drug
Apr 8, 2016 9:59am
